Set and setting means the mindset a person brings and the environment around the experience. What two published papers say about context in psychedelic research.
In psychedelic research, set means the mindset a person brings to the experience and setting means the environment it happens in. Set covers expectations and psychological state, while setting covers the physical surroundings and the social environment. Two papers in the Journal of Psychopharmacology group set and setting under the word "context" and argue that context shapes how a psychedelic experience goes.
We read both papers on October 13, 2026, as a desk review. Nobody on this site ran a session.
Set describes the person and setting describes the surroundings. Set is the mindset, expectations and psychological state someone carries into a psychedelic experience, and setting is the physical and social environment around that experience.
The 2018 paper by Carhart-Harris and colleagues places set and setting together "under the umbrella term 'context'." When these authors write about context, they mean both halves at once.
The 2016 paper by Hartogsohn names expectancy, preparation and beliefs as factors that set and setting theory treats as major.
In plain terms, the difference between set and setting is the difference between what a person brings and what surrounds them. Neither paper on our record ranks one above the other.
Carhart-Harris and colleagues tie the importance of context to the pharmacological mechanisms of classic psychedelics.
They name two mechanisms: 5-HT2A receptor agonism, meaning activation of the serotonin 2A receptor, and the plasticity associated with it. In the authors' words, these mechanisms "render their effects exceptionally sensitive to context."
The article is an opinion piece from the Psychedelic Research Group at Imperial College London and the Istituto Superiore di Sanità in Rome. It describes a study design for testing assumptions about positive interactions between psychedelics and context.
The authors also describe new findings from their group on the contextual factors that determine the quality of a psychedelic experience. They report work on how the acute experience predicts later long-term mental health outcomes. The specific results and sample sizes are not on our record.
Set and setting theory and placebo response theory are two fields that study how non-biological factors shape the response to a therapy, according to Hartogsohn. Both fields count expectancy, preparation and beliefs among those factors.
Hartogsohn separates the two fields on scope. Set and setting concerns the response to psychoactive drugs only, while placebo theory relates to all therapeutic interventions.
The two fields also speak to different readers. Placebo theory is aimed at medical professionals, and set and setting theory is aimed at professionals and drug users alike.
The third difference is purpose. Placebo theory is primarily descriptive, while set and setting theory is primarily prescriptive, "educating therapists and users on how to control and optimize the effects of drugs."
Read together, those points mean set and setting overlaps with placebo theory on factors such as expectancy and differs from it in scope, audience and purpose. The paper examines how the two theories can complement and benefit each other. It is a perspective paper, and it does not show that set and setting causes any outcome.
Carhart-Harris and colleagues describe set and setting as "a long-recognised component of the psychedelic treatment model."
The 2018 authors hope their article can inform good practice in psychedelic research, provide a roadmap for optimising treatment models and help tackle stigma. The contents of that roadmap beyond the abstract are not on our record.
Specific clinical trial protocols for managing set and setting are not on our record either.
Outside research, our guides cover state-regulated psilocybin service centers in Oregon and Colorado, including the Oregon psilocybin facilitator certification process. For the broader treatment model, read our guides on what psychedelic therapy is and integration therapy.
Neither paper on our record shows that set and setting makes a psychedelic experience safe or prevents a difficult one.
The 2018 article is an opinion piece. Its authors describe the evidence base for long-held assumptions about context as something still being developed, and they frame the goal as evidence that "can help minimise harms and maximise potential benefits." A trial result from the study design they describe is not on our record.
Hartogsohn's 2016 paper compares two bodies of theory and does not measure an effect of set and setting. His label for set and setting theory, prescriptive, describes its purpose and is not evidence that its advice works.
For safety questions outside these two papers, read our psychedelic medication safety guide. If someone is in immediate danger, go to our crisis resources page.
Psilocybin, psilocyn and MDMA are Schedule I substances under federal law.
Schedule I in 21 CFR 1308.11 lists MDMA under code 7405, psilocybin under 7437 and psilocyn under 7438.
Oregon (Measure 109) and Colorado (Proposition 122) allow adult access to psilocybin at state-regulated service centers, while psilocybin stays Schedule I federally. Our guide to whether psilocybin is legal in the US covers those programs, and our legal status by state tool covers state rules.
To read the authors' own wording on set and setting, open the 2018 Carhart-Harris article and the 2016 Hartogsohn paper on PubMed.
Set is the mindset, expectations and psychological state a person brings to a psychedelic experience. Setting is the physical and social environment where the experience happens. Carhart-Harris and colleagues group the two under the umbrella term "context" in their 2018 opinion piece.
Set and setting is the idea that a person's mindset and surroundings shape how a psychedelic experience goes. The 2018 Carhart-Harris article calls it a long-recognised component of the psychedelic treatment model. Hartogsohn's 2016 paper describes set and setting theory as primarily prescriptive and aimed at professionals and drug users alike.
Carhart-Harris and colleagues argue that 5-HT2A receptor agonism and associated plasticity render the effects of classic psychedelics exceptionally sensitive to context. They hope their article can inform good practice in psychedelic research. Specific trial protocols for set and setting are not on our record.
No source on our record shows that set and setting makes any psychedelic safe or prevents a difficult experience. The 2018 article is an opinion piece that hopes an evidence base on context can help minimise harms and maximise potential benefits. Hartogsohn's 2016 paper is a perspective paper and does not show that set and setting causes outcomes.
No. Hartogsohn writes that the two theories overlap because both study non-biological factors such as expectancy, preparation and beliefs. Set and setting concerns psychoactive drugs only and is primarily prescriptive, while placebo theory covers all therapeutic interventions and is primarily descriptive.
Psilocybin, MDMA and other Schedule I substances remain federally illegal outside authorized research. State-regulated adult access to psilocybin exists in Oregon and Colorado, as covered in this site's guides. This page gives no guidance for using any controlled substance outside an authorized setting.
Get Set and Setting research & policy updates
New trials, FDA decisions, and legal changes for Set and Setting — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.